ADVANCED ENZYME TECHNOLOGIES
|
ADVANCED ENZYME TECHNOLOGIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 15.07 | 11.72 | 11.92 | 9.45 | 10.70 |
| CEPS(Rs) | 19.09 | 15.24 | 15.40 | 12.42 | 14.20 |
| DPS(Rs) | 5.35 | 5.20 | 5.10 | 1.00 | 1.00 |
| Book NAV/Share(Rs) | 144.99 | 126.56 | 118.14 | 110.45 | 97.31 |
| Tax Rate(%) | 25.34 | 28.50 | 27.08 | 26.02 | 27.63 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 30.69 | 30.70 | 32.87 | 29.09 | 38.19 |
| EBIT Margin(%) | 31.62 | 30.15 | 30.73 | 26.57 | 32.80 |
| Pre Tax Margin(%) | 31.12 | 29.42 | 30.07 | 25.93 | 32.25 |
| PAT Margin (%) | 23.24 | 21.03 | 21.92 | 19.18 | 23.34 |
| Cash Profit Margin (%) | 28.60 | 26.77 | 27.57 | 25.65 | 29.93 |
| Performance Ratios | |||||
| ROA(%) | 10.08 | 8.55 | 9.34 | 7.78 | 10.28 |
| ROE(%) | 11.43 | 9.79 | 10.72 | 8.94 | 12.04 |
| ROCE(%) | 15.27 | 13.76 | 14.78 | 12.26 | 16.66 |
| Asset Turnover(x) | 0.43 | 0.41 | 0.43 | 0.41 | 0.44 |
| Sales/Fixed Asset(x) | 0.75 | 0.68 | 0.71 | 0.65 | 0.68 |
| Working Capital/Sales(x) | 0.80 | 0.81 | 0.89 | 0.84 | 0.98 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.33 | 1.47 | 1.42 | 1.55 | 1.47 |
| Receivable days | 63.61 | 61.31 | 58.11 | 63.55 | 60.03 |
| Inventory Days | 81.73 | 87.61 | 79.59 | 82.55 | 73.90 |
| Payable days | 56.22 | 42.35 | 50.47 | 58.32 | 55.08 |
| Valuation Parameters | |||||
| PER(x) | 16.94 | 23.80 | 29.15 | 24.52 | 26.37 |
| PCE(x) | 13.38 | 18.30 | 22.57 | 18.65 | 19.86 |
| Price/Book(x) | 1.76 | 2.20 | 2.94 | 2.10 | 2.90 |
| Yield(%) | 2.09 | 1.86 | 1.47 | 0.43 | 0.35 |
| EV/Net Sales(x) | 3.71 | 4.76 | 6.07 | 4.59 | 5.46 |
| EV/Core EBITDA(x) | 10.43 | 13.28 | 15.62 | 13.56 | 13.83 |
| EV/EBIT(x) | 11.69 | 15.80 | 19.71 | 17.24 | 16.61 |
| EV/CE(x) | 1.67 | 2.10 | 2.80 | 1.99 | 2.63 |
| M Cap / Sales | 3.83 | 4.90 | 6.23 | 4.79 | 5.96 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 17.09 | 2.09 | 15.39 | 2.13 | 5.49 |
| Core EBITDA Growth(%) | 15.95 | -5.68 | 32.44 | -12.46 | -13.43 |
| EBIT Growth(%) | 23.06 | 0.03 | 33.42 | -17.32 | -18.19 |
| PAT Growth(%) | 29.58 | -2.17 | 31.85 | -16.10 | -18.17 |
| EPS Growth(%) | 28.63 | -1.69 | 26.19 | -11.68 | -18.11 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 |
| Current Ratio(x) | 9.78 | 9.14 | 7.61 | 9.31 | 10.00 |
| Quick Ratio(x) | 8.12 | 7.51 | 6.22 | 7.71 | 8.00 |
| Interest Cover(x) | 63.28 | 41.44 | 46.58 | 41.36 | 58.89 |
| Total Debt/Mcap(x) | 0.01 | 0.01 | 0.01 | 0.01 | - |
Compare Financial Ratios of peers of ADVANCED ENZYME TECHNOLOGIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ADVANCED ENZYME TECHNOLOGIES | ₹3,330.9 Cr | -0.2% | -11.2% | -12.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹455,826.0 Cr | -2.9% | -2.3% | 21.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹247,019.0 Cr | -1.6% | 9.8% | 51.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹186,875.0 Cr | -2.6% | -2.3% | 37.5% | Stock Analytics | |
| CIPLA | ₹112,773.0 Cr | -2.2% | -6.1% | -12.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹95,570.9 Cr | -0.9% | -1.8% | -9.8% | Stock Analytics | |
ADVANCED ENZYME TECHNOLOGIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ADVANCED ENZYME TECHNOLOGIES | -0.2% |
-11.2% |
-12.7% |
| SENSEX | -1.1% |
-3.6% |
-5.3% |
You may also like the below Video Courses
